Robert Schlossman

19.8k total citations · 4 hit papers
161 papers, 10.9k citations indexed

About

Robert Schlossman is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert Schlossman has authored 161 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Hematology, 95 papers in Molecular Biology and 70 papers in Oncology. Recurrent topics in Robert Schlossman's work include Multiple Myeloma Research and Treatments (123 papers), Protein Degradation and Inhibitors (51 papers) and Peptidase Inhibition and Analysis (36 papers). Robert Schlossman is often cited by papers focused on Multiple Myeloma Research and Treatments (123 papers), Protein Degradation and Inhibitors (51 papers) and Peptidase Inhibition and Analysis (36 papers). Robert Schlossman collaborates with scholars based in United States, Switzerland and Spain. Robert Schlossman's co-authors include Kenneth C. Anderson, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Constantine S. Mitsiades, Nicholas Mitsiades, Steven P. Treon, Yu‐Tzu Tai and Klaus Podar and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Robert Schlossman

159 papers receiving 10.7k citations

Hit Papers

Thalidomide and immunomodulatory derivatives augment natu... 2000 2026 2008 2017 2001 2000 2002 2003 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    2001 740 citations Noopur Raje, Teru Hideshima et al. Blood profile →
  2. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
    2000 708 citations Teru Hideshima, Dharminder Chauhan et al. Blood profile →
  3. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    2002 630 citations Paul G. Richardson, Robert Schlossman et al. Blood profile →
  4. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    2003 575 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →

Peers

Robert Schlossman
A. Keith Stewart United States
Antonio Palumbo Italy
Xavier Leleu France
Ravi Vij United States
Asher Chanan‐Khan United States
Jonathan L. Kaufman United States
Joan Bladé Spain
Henk M. Lokhorst Netherlands
María‐Victoria Mateos Spain
Hervé Avet‐Loiseau France
A. Keith Stewart United States
Robert Schlossman
Citations per year, relative to Robert Schlossman Robert Schlossman (= 1×) peers A. Keith Stewart

Countries citing papers authored by Robert Schlossman

Since Specialization
Citations

This map shows the geographic impact of Robert Schlossman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Schlossman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Schlossman more than expected).

Fields of papers citing papers by Robert Schlossman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Schlossman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Schlossman. The network helps show where Robert Schlossman may publish in the future.

Co-authorship network of co-authors of Robert Schlossman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Schlossman. A scholar is included among the top collaborators of Robert Schlossman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Schlossman. Robert Schlossman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Richardson, Paul G., Sarah A. Holstein, Robert Schlossman, et al.. (2017). Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy. 18(18). 1975–1985. 8 indexed citations
2.
Batal, Ibrahim, Vanesa Bijol, Robert Schlossman, & Helmut G. Rennke. (2013). Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in a Kidney Allograft. American Journal of Kidney Diseases. 63(2). 318–323. 10 indexed citations
3.
Gaballa, Mahmoud, Jacob P. Laubach, Robert Schlossman, et al.. (2012). Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology. 5(1). 51–68. 24 indexed citations
4.
Richardson, Paul G., Jacob P. Laubach, Robert Schlossman, et al.. (2012). The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal Of Haematology. 88(5). 446–449. 8 indexed citations
5.
Laubach, Jacob P., Robert Schlossman, Constantine Mitsiades, Kenneth C. Anderson, & Paul G. Richardson. (2011). Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Review of Hematology. 4(1). 51–60. 19 indexed citations
6.
Ghobrial, Irene M., Nikhil C. Munshi, Brianna Harris, et al.. (2011). A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. American Journal of Hematology. 86(7). 573–578. 19 indexed citations
7.
Richardson, Paul G., Jacob P. Laubach, Robert Schlossman, et al.. (2011). The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*. European Journal Of Haematology. 88(1). 1–7. 4 indexed citations
8.
McMillin, Douglas W., Jake Delmore, Joseph Negri, et al.. (2011). Molecular and cellular effects of multi‐targeted cyclin‐dependent kinase inhibition in myeloma: biological and clinical implications. British Journal of Haematology. 152(4). 420–432. 24 indexed citations
9.
McMillin, Douglas W., Melissa Ooi, Jake Delmore, et al.. (2009). Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Cancer Research. 69(14). 5835–5842. 105 indexed citations
10.
11.
Treister, Nathaniel S., Paul G. Richardson, Robert Schlossman, Kenneth D. Miller, & Sook‐Bin Woo. (2008). Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 105(6). e1–e4. 19 indexed citations
12.
Ghobrial, Irene M., Xavier Leleu, Evdoxia Hatjiharissi, et al.. (2007). Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs. 12(1). 155–163. 7 indexed citations
13.
Koreth, John, Corey Cutler, Benjamin Djulbegović, et al.. (2007). High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Biology of Blood and Marrow Transplantation. 13(2). 183–196. 150 indexed citations
14.
Tai, Yu‐Tzu, Xianfeng Li, Laurence Catley, et al.. (2005). Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40–Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. Cancer Research. 65(24). 11712–11720. 132 indexed citations
15.
Richardson, Paul G., Robert Schlossman, Constantine S. Mitsiades, et al.. (2005). Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma. Clinical Lymphoma & Myeloma. 6(2). 84–88. 5 indexed citations
16.
Chauhan, Dharminder, Daniel Auclair, Teru Hideshima, et al.. (2002). Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 21(9). 1346–1358. 134 indexed citations
17.
Alyea, Edwin P., Edie Weller, David C. Fisher, et al.. (2002). Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation. 8(11). 601–607. 19 indexed citations
18.
Hideshima, Teru, Dharminder Chauhan, Robert Schlossman, Paul G. Richardson, & Kenneth C. Anderson. (2001). The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 20(33). 4519–4527. 327 indexed citations
19.
Orsini, Enrica, Edwin P. Alyea, Antoinette Chillemi, et al.. (2000). Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biology of Blood and Marrow Transplantation. 6(4). 375–386. 59 indexed citations
20.
Schlossman, Robert & Kenneth C. Anderson. (1999). Bone marrow transplantation in multiple myeloma. Current Opinion in Oncology. 11(2). 102–102. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Antonio Palumbo Breakdown of academic impact, for papers by Xavier Leleu Breakdown of academic impact, for papers by Ravi Vij Breakdown of academic impact, for papers by Asher Chanan‐Khan Breakdown of academic impact, for papers by Jonathan L. Kaufman Breakdown of academic impact, for papers by Joan Bladé Breakdown of academic impact, for papers by Henk M. Lokhorst Breakdown of academic impact, for papers by María‐Victoria Mateos Breakdown of academic impact, for papers by Hervé Avet‐Loiseau
Rankless by CCL
2026